Selecting Optimal Antiangiogenic Strategies for Patients With Hepatocellular Carcinoma

STATEMENT OF NEED

Hepatocellular carcinoma is the sixth most common tumor globally, with an increasing incidence in the United States and Europe. The malignancy is the third leading cause of cancer-related death worldwide and the leading cause of death in patients with cirrhosis. Approximately 40,710 new cases are diagnosed in the United States annually and 28,920 people die of the disease. Patients with HCC continue to have a dismal prognosis, with a 5-year survival rate of 18%. This is due in part to most tumors being diagnosed at advanced stages, for which there is a dearth of effective treatment options.

TARGET AUDIENCE

Medical oncologists, hepatologists, gastroenterologists, oncology nurse practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with hepatocellular carcinoma.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Describe the pathogenesis of HCC and the scientific foundation for antiangiogenic therapies
2. Evaluate emerging efficacy and safety data on the use of antiangiogenic therapies for patients with advanced HCC
3. Assess tumor response in patients receiving antiangiogenic therapies for advanced HCC

FACULTY

Thomas A. Abrams, MD (Chairperson)
Assistant Professor of Medicine
Harvard Medical School

REGISTRATION

There is no fee to participate in or claim CME/CE credit for this activity.

Please note that the Postgraduate Institute for Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Jointly Provided by

Postgraduate Institute for Medicine and i3 Health

ACCME Commendation LogoThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and i3 Health. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Thomas A. Abrams, MD has served as a consultant for Bayer, Bristol-Myers Squibb, Celgene, Aduro, and Kaleido, and has received grants/research support from Eli Lilly and Celgene.

Planners and Managers

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must:

1. Watch the online video
2. Pass the posttest with a score of ≥80%
3. Complete the activity evaluation
4. Download or print their Certificate of Credit

UNAPPROVED USE DISCLOSURE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Bayer.

CONTACT INFORMATION

If you have technical queries about this activity or issues with your CME certificate, please contact support@i3health.com. For questions regarding the activity’s accreditation, please contact the accredited provider at inquiries@pimed.com.